Form 4: Phathom Pharmaceuticals Director Frank Karbe Reports Stock and Option Transactions

Director Frank Karbe reports acquisition of stock and stock options in Phathom Pharmaceuticals.

Summary

• On May 23, 2024, Frank Karbe, a director of Phathom Pharmaceuticals, acquired 10,500 shares of common stock and disposed of 19,500 shares.
• Karbe also acquired stock options for 17,500 shares of common stock at an exercise price of $10.30, expiring on May 22, 2034.
• The 10,500 shares were received as Restricted Stock Units (RSUs) under the Non-Employee Director Compensation Program, vesting on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued board service.
• The option for 17,500 shares was also granted under the Non-Employee Director Compensation Program, vesting on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued board service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of RSUs and options is positive, but the disposal of shares is a slight negative. Overall, it's a routine transaction.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future.

Negatives

• The disposal of 19,500 shares by the director could be interpreted negatively by investors.

Risks

• Director share disposals can sometimes indicate a lack of confidence in the company's prospects, although this is not necessarily the case here.

Future Outlook

The vesting of the RSUs and stock options is contingent on continued service on the board, suggesting an ongoing commitment from the director.

Industry Context

Director transactions are common and closely watched indicators of management's sentiment regarding the company's prospects. These transactions are part of standard compensation packages for directors.

Comparison to Industry Standards

• Director compensation packages often include stock options and RSUs to align their interests with those of shareholders.
• Vesting schedules tied to continued service are standard practice in the pharmaceutical industry to ensure long-term commitment.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the director's actions.

Key Dates